Front-Line AIDS Drugs Show Staying Power: Study
December 20, 2007
A new study offers encouraging news about first-line HIV/AIDS treatments and the development of drug-resistant virus.
British researchers examined data on 7,916 HIV patients taking the standard three-drug cocktail of nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and protease inhibitors. They found that 167 had developed extensive resistance to all three drug classes. The study population had a 9.2 percent chance of developing three-drug resistance after 10 years, the authors reported.
The study's findings are particularly welcome news for the developing world. When primary treatment fails, doctors must turn to second- and third-line drugs. In resource-poor locales, these are much more expensive and difficult to obtain. "In such settings, only one or two regimes are normally available, which results in disastrous consequences when these regimes fail," according to a commentary published with the study.
The news, however, comes with caveats:
The full report, "Risk of Extensive Virological Failure to the Three Original Antiretroviral Drug Classes over Long-Term Follow-up from the Start of Therapy in Patients with HIV Infection: An Observational Cohort Study," and the commentary, "A Wake-Up Call for Global Access to Salvage HIV Drug Regimens," were published in The Lancet (2007;370(9603):1923-1928 and 1885-1887).
Agence France Presse
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.